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Posttranscriptional regulation of gene expression of mRNAs containing adenine-uridine rich elements (AREs) in their 3′
untranslated regions is mediated by a number of diﬀerent proteins that interact with these elements to either stabilise or destabilise
them. The present review concerns the TPA-inducible sequence 11 (TIS11) protein family, a small family of proteins, that appears
to interact with ARE-containingmRNAs and promote their degradation. This family of proteins has been extensively studied in the
past decade. Studies have focussed on determining their biochemical functions, identifying their target mRNAs, and determining
their roles in cell functions and diseases.
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1. Introduction
Mechanisms of posttranscriptional gene regulation by
micro-RNA (miRNA) and short interfering RNA (siRNA)
have been highlighted in recent years as having important
roles in control of a variety of developmental and functional
processes. The present review concerns a small family of
proteins, the 12-O-tetradecanoylphorbol-13-acetate (TPA)
inducible sequence 11 (TIS11) family, which also function
in posttranscriptional gene regulation and whose func-
tions may overlap and interact with miRNA and siRNA
control mechanisms. The TIS11 family consists of four
mammalian members and include TIS11 (ZFP36, TTP,
Nup475, GOS24), TIS11b (Berg36, ERF-1, ZFP36L1, BRF-
1), and TIS11d (ZFP36L2, ERF-2, BRF-2). The fourth family
member described in rodents, Zfp36l3, was expressed in
mouse placenta, but was not detected in human placenta
or other human tissues [1]. TIS11-like proteins have also
been identified in drosophila and yeast [2–4]. These proteins
contain two tandemly repeated zinc finger motifs through
which they bind to adenine uridine (AU) rich elements
(AREs) in mRNA and mediate ARE-mediated mRNA decay
[5]. Table 1 lists the three human TIS11 family members,
their chromosomal locations as well as reported mRNA
targets. This family of proteins have been reported to
promote deadenylation, decapping, and finally degradation
of mRNAs by either exosome (3′-5′ degradation) or XRN1
exonuclease (5′-3′ degradation) [6].
AREs are found mostly at the 3′ end of many mRNAs
encoding cytokines, transcription factors, cell cycle regula-
tors, and apoptosis regulators. It is estimated that up to
8% of mRNAs may contain AREs [7]. AREs are subdivided
into three classes: Class I, Class II, and Class III. Class II
is further subdivided into Class IIA, IIB, IIC, IID, IIE [6].
Class I is characterised by the AUUUA motif and a U-rich
region. Class III is characterised by a U-rich sequence found
in, for example, the mRNA of c-jun. Class IIA contains five
consecutive AUUUA pentamer sequences; Class IIB contains
four consecutive AUUUA pentamers; Class IIC contains
three consecutive AUUUA pentamers; Class IID contains
two consecutive AUUUA pentamers, and finally Class IIE
contains one AUUUA motif [6].
2. The TIS11 Family in Posttranscriptional
Gene Regulation
One of the first indications that the prototype TIS11 protein
functions as an AU binding protein came from work
which showed that TIS11 inhibited TNFα production from
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macrophages by destabilising its messenger RNA (mRNA)
and this appeared to be due to direct binding of TIS11 to
the TNFα ARE [8]. It was later shown that the optimal
and minimally required RNA sequence for TIS11 binding is
UUAUUUAUU [9–12]. The adenine residues and the spacing
between them are critical in ensuring a stable association
between the TIS11 peptide and RNA, even though TIS11
was still able to strongly bind to an AUUUUA peptide, and
intermediately to AUUA and AUUUUUA peptides [9, 10].
TIS11 interaction with the RNA sequence is of relatively high
aﬃnity [10]. It should be noted that AREs are found at the 3′
end of each of the TIS11 family mRNAs suggesting that they
may regulate themselves by a negative feedback loop [13, 14].
Overexpression of human TIS11 in HEK293 cells caused
significant reduction in the levels of an artificial reporter
mRNA containing part of the TNF-α 3′ untranslated region
(3′ UTR), and this was dependent on the amount of
TIS11 plasmid transfected [32]. Similar eﬀects were seen
for rat TIS11b or Xenopus TIS11d, although TIS11d was
less eﬃcient in inducing TNF-α reporter mRNA decay than
TIS11 and TIS11b [32]. Two zinc finger motifs in TIS11 are
necessary and suﬃcient for binding to the AREs, and also
mediate TNF-α mRNA decay [32]. Similarly, other studies
reported that TIS11 and other members of the TIS11 family
can also mediate decay of mRNA for GM-CSF and IL-3
[15, 33]. Critical residues in the human TIS11 family zinc
finger domains for binding to the TNF-α ARE probe or
GM-CSF ARE probes were Cys124, Cys147, His128, Cys162,
and His166, and mutations of these residues to other amino
acids completely abolished TIS11 binding [39]. In the same
study it was shown that coexpression of wild type TIS11
and a Cys124R nonbinding mutant resulted in stabilisation
of artificial reporter TNF-α mRNA, even though wild type
TIS11 was able to bind reporter TNF-α mRNA [39]. This
finding suggested that the presence of a nonbinding mutant
acts as a dominant negative over TIS11 destabilising activity,
possibly by interacting with proteins that regulate TIS11
destabilising function [39].
TIS11-dependent degradation of mRNA requires dead-
enylation [40]. Deadenylation is strongly induced by TIS11
when two nonamers (UUAUUUAUU) are present in a
sequence, whereas deadenylation and mRNA degradation
by TIS11 in probes containing only one nonamer is much
weaker [12]. The ability of TIS11 to promote deadenylation
was dependent on the presence of Mg+2 and it was suggested
that there is involvement of PolyA specific ribonuclease
(PARN) in the process. It was shown that TIS11 requires
PARN to promote deadenylation of an ARE containing
mRNA probe [40]. Association between TIS11 and PARN
is indirect rather than direct and other proteins may form
the bridge between them. Alternatively, the presence of
TIS11 may displace an ARE stabilising factor that inhibits
deadenylation caused by PARN [40]. Another study using
immunoprecipitation demonstrated that TIS11 does not
associate directly with PARN [41]. It was also shown
that TIS11 co-immunoprecipitates with hDcp1 and hDcp2
(decapping enzymes), hXrn1 (5′-3′ exonuclease), hCcr4
(deadenylase), hRrp4 (a component of the exosome), or
hEdc3 (enhances the activity of the decapping enzymes)
through the N-terminal domain, whereas the zinc fingers and
the C-terminal domain are not involved in these interactions
[41, 42]. Additionally, deletion of the N-terminal domain
of TIS11 partially abrogated induction of mRNA decay by
TIS11. It was therefore proposed that TIS11 is involved
in deadenylation and degradation of mRNA by recruiting
enzymes such as hDcp1, hDcp2 and hCcr4 through the
N-terminal domain [41]. Other transacting elements may
also be involved in TIS11 function recruited through the
C-terminal domain, since deletion of this domain in both
TIS11 and TIS11b resulted in stabilisation of a β-globin
mRNA containing AREs [41]. One such element may be the
exosome, a multicomponent complex with 3′-5′ exonuclease
activity, and it was reported that TIS11 requires and recruits
the exosome specifically in ARE containing mRNA probes,
to mediate degradation of a deadenylated mRNA [43]. It
was also shown that the exosome consists of 14 diﬀerent
components, among which are hRrp4, hRrp40, hRrp41,
hRrp42, hRrp43, hRrp46, hCsl4, and hMtr3 [43]. It seems
likely that TIS11 mediated mRNA degradation involves
multiple enzymes including PARN, decapping enzymes such
as hDcp1, hDcp2, hEdc3, exonucleases including the exo-
some, and Xrn1 (5′-3′ exonuclease) as well, to preferentially
degrade ARE containing mRNAs [42, 43]. Figure 1 shows the
pathways and major components of ARE mediated mRNA
decay.
Reported mRNA targets of the TIS11 family include
TNF-α inmany cell types [14, 24, 44–47], GM-CSF [15], IL-3
[16], IL-2 [21], IL-6 [17], IL-10 [30], Ccl2 and Ccl3 [24], 1,4-
galactosyltransferase [22], vascular endothelial growth factor
(VEGF) [29], cyclooxygenase-2 [18], plasminogen activator
inhibitor type 2 [19], paired-like homeodomain 2 (Pitx2)
[20], E47 [28], polo-like kinase 3 [31], and TIS11 itself [14].
VEGF mRNA was also reported to be a target of TIS11b
[35] although in TIS11b deficient fibroblasts VEGF levels
were shown to be elevated as a consequence of increased
translation rather than an eﬀect on VEGF mRNA [37]. More
recently, TIS11b has been reported to target and degrade
steroid acute regulatory (STAR) protein mRNA [38]. Utili-
sation of siRNA inhibition for TIS11 revealed that it targets
FOS and p21 in the THP-1 cell line and primary human
monocytes [26] and IL-12 and MIP-2 in macrophages [23].
Similarly, TIS11 is involved in the regulation of c-myc and
cyclin-D following treatment of glioblastoma and prostate
cancer cell lines with rapamycin [25]. This suggests that
TIS11 also regulates certain transcription factors and cell
cycle regulators. A global search for novel mRNA targets
of TIS11 identified 250 potential targets and characterised
immediate early response gene 3 (Ier3) mRNA as a novel
target [27]. Notably, in this study Ier3 was clearly shown not
to be a target for TIS11b [27] and in a later study polo-
like kinase 3 was shown also to be a target for TIS11 but
not TIS11b or TIS11d [31]. These examples illustrate that
mRNA targets of TIS11 family members may be diﬀerent for
diﬀerent family members. In fact, there is growing awareness
in the field that many in vitro assays designed to measure
mRNA interaction and decay may identify “nonphysiological
targets” and that “physiological targets” of TTP family
members can best be determined by analysis of mRNA
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Figure 1: Pathways and major components of ARE-mediated mRNA decay by TIS11 proteins. TIS11 protein binds to the ARE sequence in
the 3′ UTR and recruits deadenylases either directly (hCcr4) or indirectly (PARN). Deadenylated mRNA can be recruited by the exosome,
a multiprotein structure containing proteins such as Rrp4, Rrp40, Rrp41, and PM-Scl75 that form the 3′ to 5′ exoribonuclease complex.
Decapping of mRNA can follow deadenylation mediated by decapping enzymes such as Dcp1 and Dcp2 and degradation of mRNA can then
be mediated by the 5′ to 3′ Xrn1 exonuclease.
degradation kinetics in knockout mice or cells derived from
knockout mice [27]. Another more recent global analysis of
TIS11 targets identified 137 potential TIS11 mRNA targets
[30]. Interestingly, only a subset of the putative TIS11 targets
contained the UUAUUUAUU sequence. This implies that
either the RNA binding specificity of TIS11 proteins is not
fully understood or that TIS11 proteins can be indirectly
recruited to mRNA targets via other RNA-binding proteins,
or that many false positives have been indentified in target
screens. Table 1 summarises the reported mRNA targets for
TIS11 family proteins and reported mechanisms.
A number of recent studies have reported links between
TIS11 andmiRNA functions and processes. Dicer, an enzyme
required in the processing of miRNAs, was needed for TIS11
mediated degradation of TNFα ARE [48]. Furthermore,
these studies revealed that miRNA16 can pair with eight
bases in the TNFα ARE and this pairing is required for
TIS11 mediated degradation of TNFα ARE [48]. TIS11
and miR16 do not bind directly to each other but interact
through association with Argonaute/eiF2C family members
[48]. Thus, TIS11 mediated mRNA degradation may require
components of the miRNA processing pathway and indeed
miRNA and TIS11 proteins may act codependently in medi-
ating degradation. TIS11 was also identified as a component
of the RNAi pathway by a genome wide screen in drosophila
melanogaster [49]. TIS11 genes contain many predicted
targets for miRNA suggesting another level of complexity
in the interrelationship between TIS11 family members and
miRNAs [50]. A picture is therefore emerging of potentially
complex interplay of diﬀerent mechanisms of posttranscrip-
tional gene regulation which include the TIS11 family.
3. Identification of Human TIS11
Family Members
Human TIS11 is located on chromosome 19q13.1, and was
isolated and cloned by several groups after stimulation of
cells with serum, TPA, or insulin [51–53]. Human TIS11b
is located on chromosome 14q22-24 and was isolated from
chronic lymphocytic leukemia cells (CLL) after stimulation
with TPA [54, 55], from human cDNA libraries probed with
the rat cMG1 [13] or as a gene that reversed the phenotype
of mutant H1080 cells which were unable to degrade IL-3
mRNA [34]. Finally human TIS11d is located on 2p22.3-
p21 and was isolated from human cDNA libraries probed
with the mouse TIS11d mRNA [56]. The sequence of each
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Table 1: Human TIS11 family members and reported mRNA targets of the TIS11 family.
Gene Alternative names Chromosomal location Reported mRNA targets reference mechanism
TIS11 ZFP36, TTP, Nup475, GOS24 19q13.1 TNF∗ [8] mRNA stability
GM-CSF [15] mRNA stability
IL-3 [16] mRNA stability
IL-6 [17] mRNA stability
cyclooxygenase [18] mRNA stability
PAI type 2 [19] mRNA stability
Pitx2 [20] mRNA stability
TIS11 [14] mRNA stability
IL-2 [21] mRNA stability
1,4galactosyltransferase [22] mRNA stability
IL-12 [23] ?
Ccl2 [24] mRNA stability
Ccl3 [24] mRNA stability
c-myc [25] mRNA stability
cyclin D1 [25] mRNA stability
Fos [26] mRNA stability
Ier3 [27] mRNA stability
Genome analysis 250 mRNAs [27] mRNA stability
MIP-2 [23] ?
p21 [26] mRNA stability
E47 [28] mRNA stability
VEGF [29] mRNA stability
IL-10 [30] mRNA stability
Genome analysis 137 mRNAs [30] mRNA stability
polo-like kinase 3 [31] mRNA stability
TIS11b ZFP36L1, Berg36, ERF-1, BRF-1 14q22-24 TNF [32] mRNA stability
GMCSF [33] mRNA stability
IL-3 [34] mRNA stability
VEGF [35] mRNA stability
c-IAP2 [36] mRNA stability
VEGF [37] translation
STAR [38] mRNA stability
TIS11d ZFP36L2, ERF-2, BRF-2 2p22.3-p21 TNF [32] mRNA stability
GM-CSF [33] mRNA stability
IL-3 [33] mRNA stability
∗
Targets in bold confirmed in cells derived from knockout animals are so-called “physiological” targets.
of the three human genes shows little variation between
individuals, and most polymorphisms are detected in the
introns, promoter, and 3′ UTR regions [57]. Thirteen poly-
morphisms were detected in the protein-coding regions of
the three TIS11 family genes and six of these would result in
amino acid changes. In TIS11b a polymorphism generating
a dinucleotide substitution was detected that would prevent
splicing of the single intron of TIS11b but to date the
significance of this is unknown [57]. Further polymorphisms
of TIS11 were identified in a more recent study and one, an
C to T transition in the protein coding domain of TIS11, was
significantly associated with rheumatoid arthritis in African-
Americans [58].
TIS11, TIS11b, and TIS11d have all been associated with
induction of mRNA decay (see Table 1), and even though
redundancy in their function has been suggested, studies
with knock-out mice and analysis of tissue distribution
suggest that they may have cell specific regulation and
functions. TIS11 knock-out mice appear normal at birth but
later develop severe cachexia, autoimmunity, patchy alopecia,
arthritis, and conjunctivitis, which can be reversed by
administration of anti-TNF-α antibody [44]. TIS11b knock-
outmice do not survive to birth but die in utero between days
E8 and E13, due either to failure in chorioallontoic fusion
[59], or to defective extraembryonic vasculogenesis [37].
Mice in which a truncated form of TIS11d was generated,
which left the RNA binding domain and the nuclear export
signal intact [60], appeared normal at birth, but females were
infertile. Expression of the TIS11 family in mouse tissues has
shown that the TIS11 protein is highly expressed in spleen,
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thymus, lung, large intestine, and liver, weakly expressed in
brain and pancreas but is not expressed at all in the testis and
uterus [61]. TIS11b is highly expressed in kidneys, liver, lung,
pancreas, and heart, and weakly in skeletal muscle, colon,
thymus, spleen, small intestine, brain, and peripheral blood
leukocytes [62]. TIS11d is highly expressed in lung, liver,
skeletal muscle, kidneys, pancreas, placenta, and less strongly
in heart and brain [63].
4. Structure of TIS11 Family Members
The structures of the first zinc finger motif of TIS11 [64]
and human TIS11d before and after binding to an ARE
probe have been reported [65]. The spacing between the
cysteines and histidine in the zinc fingers (CX8CX5CX3H)
and the length of the linker between the zinc finger motifs
are conserved between TIS11, TIS11b, and TIS11d. Because
of the similarity of the zinc finger motifs between the three
family members, it is expected that the model of mRNA
binding to TIS11d will apply to all family members. The first
zinc finger motif of TIS11 was found to be very diﬀerent in
comparison with other metal and zinc binding core domains,
in terms of diameter and thickness [64]. For human TIS11d
each of the two zinc fingers is folded independently into a
compact domain connected by a linker sequence [65]. The
structure is stabilised by binding of zinc to side chains of
Cys159, Cys168, Cys174, His178 for the first zinc finger (ZF1)
motif and Cys197, Cys206, Cys212, His216 for the second zinc
finger (ZF2). Hydrogen bonds and van der Waals forces are
involved in further stabilisation of this structure [65]. The
orientation of the fingers is fixed, because the linker region
has a relatively rigid structure stabilised by hydrogen bonds
at each end and has little flexibility apart from the central
region (residues 186-189) [65]. TNF-α ARE was used as a
probe in this study, with the sequence 5′-UUAUUUAUU-3′.
Zinc finger 1 (Arg153-Phe180) interacted with a single UAUU
subsite on the 3′ end while zinc finger 2 (Lys191-Ala218)
interacted with the same subsite on the 5′ end.
5. Regulation of the TIS11 Family at
the mRNA Level
TIS11 family mRNAs are induced by TPA in a wide variety
of cells including CLL cells, mouse fibroblasts, human
epithelial cells, and PC phaeochromocytoma cells [53, 54].
Insulin can induce TIS11 in NIH3T3 mouse fibroblasts [66]
but in RIE-1 cells only TIS11b is up regulated by insulin
while the other two family members remain unaﬀected
[67]. Lipopolysaccharide (LPS) induces TIS11 as early as 30
minutes poststimulation in murine macrophage RAW264.7
cells or human macrophages (THP-1) [14, 68, 69]. TIS11
was also induced by LPS in primary human white blood cells
including lymphocytes, monocytes, and neutrophils [70].
TIS11 can be induced by GM-CSF in myeloid cells [71] and
by TGF-β in a T-cell line [72] or a combination of TPA and
ionomycin in T lymphocytes [73]. TIS11 can be induced
by anisomycin (a p38 activator) and further induced by a
combination of anisomycin plus IFN-γ or IFN-β as early as
1 hour poststimulation in mouse embryonic fibroblasts [24].
In the same study it was shown that addition of IFN-γ to LPS
treated primary mouse bone marrow macrophages further
increased induction of TIS11mRNA in comparison with LPS
treated cells [24]. Glucocorticoids have also been reported
to induce TIS11 mRNA and protein in lung epithelial cells
and this induction may well be important for glucocorticoid
mediated control of inflammatory gene expression [74, 75].
The second family member, TIS11b, has been shown to be
induced by TPA, bryostatin, and rituximab in CLL cells
[54, 76, 77], calcium ionophore, anti-IgM and anti-CD20 in
Burkitt’s lymphoma cell lines [55, 78], insulin in RIE-1 cells
[67] parathyroid hormone in human primary osteoblasts
[79] or adrenocorticotropic hormone (ACTH) hormone in
adrenocortical cells [80].
An important consideration is that the kinetics of
induction of the mRNA for TIS11 genes appears to be
dependent on the type of stimulus and cell type. For example,
TIS11 mRNA is evident at 15 minutes after insulin or serum
stimulation inmouse fibroblasts returning to almost baseline
levels at two hours [66, 81]. In RAW264.7 cells, TIS11 mRNA
induction by LPS is biphasic with the first peak at one
hour and the second peak at five hours poststimulation
[69]. It has been shown that both phases of the biphasic
TIS11 mRNA induction after LPS treatment in RAW264.7
are regulated through the p38 pathway at the mRNA level
[69] and p38 and ERK pathway at the protein level [82].
Similarly TIS11b peaks at two hours poststimulation and is
clearly above basal levels at four hours after stimulation in
insulin treated RIE-1 cells [67] but in ACTH treated human
adrenocortical cells, peak induction of the gene occurs at
three hours poststimulation and is above the basal levels
for up to 24 hours poststimulation [80]. TPA stimulation
of CLL cells induced TIS11b more strongly and earlier than
bryostatin [76] and in the BL60-2 Burkitts lymphoma cell
line, anti-IgM induced TIS11b more strongly than anti-
CD20 stimulation [78]. H7 (a broad specificity inhibitor for
the PKC and PKA pathways) did not have any eﬀect on
induction of TIS11b mRNA by TPA or bryostatin in CLL
cells [76]. Similarly, induction of TIS11b in RIE-1 cell line by
insulin was unaﬀected by PKC inhibition, but inhibition of
PI3K pathway by wortmannin partially abrogated induction,
whereas the same PI3K inhibitor had no eﬀect on induction
of TIS11b by TPA [67].
6. Regulation of the TIS11 Family at
the Protein Level
The TIS11 family is also regulated at the protein level through
either phosphorylation and/or localisation in diﬀerent cellu-
lar compartments.
6.1. Phosphorylation. The TIS11 protein was suggested to be
phosphorylated since it was noticed that stimulation of the
NIH3T3 cell line with various stimuli such as serum, TPA,
platelet-derived growth factor (PDGF), fibroblast growth
factor (FGF) for 2 hours, induced TIS11 protein detected as
45 kDa protein and not as the predicted 33 kDa protein [83].
In this particular study, phosphorylation of TIS11 was shown
to be partially regulated by the p42 mitogen activated protein
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kinase (MAPK) pathway, which phosphorylates Ser220 in
mouse TIS11 [83]. In another study in LPS stimulated
murine macrophages, TIS11 protein was evident at 75
minutes poststimulation as a 36 kDa protein, and increased
in size over time up to 45 kDa at 240minutes poststimulation
[84]. TIS11 protein is a substrate for MAPK p38α and p38β
isoforms which probably control multiple phosphorylation
events [84]. TIS11 phosphorylation was also reported to
be mediated by the p38-regulated MAPK activated protein
kinase 2 (MK2) [68]. Ser52, Ser178, Thr249, Thr250, Ser264,
Ser80/82 were suggested to be the sites of phosphorylation by
MK2 in murine TIS11 and Ser264 and Thr250 were suggested
to be regulated by the p38a pathway [85]. Addition of a
p38 inhibitor to RAW 264.7 cells previously stimulated by
LPS for 2 hours resulted in rapid TIS11 dephosphorylation
and degradation [82]. TIS11 phosphorylation is therefore in
equilibrium with dephosphorylation probably mediated by
protein phosphatase 2A [86]. Major phosphorylation sites
responsible for murine TIS11 stabilisation were found to be
Ser52 and Ser178 which were phosphorylated byMK2 [82, 87].
The importance of Ser52 phosphorylation for the cyto-
plasmic localisation of murine TIS11 was demonstrated in
a study which also suggested that Ser178 is important for
this localisation [82]. Interestingly, Ser178 is also present in
murine TIS11b and phosphorylation of this site creates a
binding site for the 14-3-3 β isoform [85]. This is not the
only isoform of 14-3-3 that the TIS11 family can bind to
and it has been shown by a yeast two hybrid system that
all TIS11 family members bind equally well to 14-3-3 η
and β isoforms [88]. A study using MudPIT or MALDI/MS
methods showed that the major phosphorylation sites in
human TIS11 when purified from HEK293 cells were Ser66,
Ser88, Thr92, Ser169, Ser186, Ser197, Ser218, Ser228, Ser276,
Ser296 [89]. Ser197, Ser218, and Ser228 were predicted to be
potential sites for protein kinase A, glycogen synthase kinase-
3, and extracellular-signal-regulated kinase 1 (both Ser218
and Ser228), respectively [89].
Phosphorylation of TIS11 may alter its function as a
destabilizing AU binding protein. One study showed that
transfection of cells with TIS11 and MKK6, which activates
p38, resulted in phosphorylation of TIS11 protein but this
did not aﬀect TIS11 ability to induce mRNA decay [69].
Another study using a series of serine or threonine mutants,
alone or in combination, showed that these phosphorylation
events did not alter the function of TIS11 in terms of TNF-α
induced destabilisation or mRNA binding and deadenylation
[47]. A further study showed that cotransfection of HEK293
cells with TIS11 and MKK6(E) dominant active MKK6
resulted in a slight increase in the half life of a TNF-α
construct in comparison with cells transfected with TIS11
alone, suggesting some deactivation or inhibition of TIS11
function following phosphorylation [84]. Furthermore, it
was reported that phosphorylation of murine TIS11 espe-
cially at Ser178 inhibited its binding ability to TNF-α ARE
and thus that the unphosphorylated TIS11 is active in
mRNA degradation [87]. It was proposed that reduced
binding activity of phosphorylated murine TIS11 could be
due to competitive binding with 14-3-3 proteins because
phosphorylation of Ser52 and Ser178 has been reported to
induce binding to 14-3-3 proteins [87]. More recently, it
was reported that phosphorylation of human TIS11b did
not aﬀect its ability to bind to AREs and recruit RNA
degradation enzymes but did nonetheless inhibit its ability to
degrade ARE-containing mRNA [90]. Finally, another study
involving human TIS11b, showed that phosphorylation of
TIS11b by protein kinase B at Ser92 abrogated mRNA decay
of an IL-3 ARE containing probe induced by overexpression
of TIS11b [91].
6.2. Subcellular Localisation of TIS11 Family Members. In
many cell types, TIS11 is expressed at very low/undetectable
levels in the nucleus and cytoplasm of unstimulated cells and
is almost entirely expressed in the cytoplasm of stimulated
cells [82]. However, there was one early report showing
that TIS11 is nuclear and remains nuclear after stimulation
with serum [51]. Another exception appears to be human
umbilical vein endothelial cells (HUVEC) in which TIS11
is cytoplasmic in resting HUVEC and becomes nuclear
after stimulation with TNF-α [22]. Nuclear to cytoplasmic
shuttling of murine Tis11 has been shown to be regulated
through induction of phosphorylation at Ser52 and Ser178,
primarily by the p38 pathway [82]. Hypophosphorylated
forms of TIS11 were found to be nuclear and highly
susceptible to proteasomal degradation [82].
Murine TIS11 has a nuclear export signal (NES) between
amino acids 1–15 [92]. For murine TIS11b B the NES has
been mapped between amino acids 305–313 and for murine
TIS11d between amino acids 471–479 [92]. In a separate
study, the rat TIS11 nuclear localisation signal (NLS) was
mapped to the region containing the tandem repeats of the
zinc finger motif (amino acids 88–161), and Arg127 and
Arg131, which are located in the linker region between the two
zinc finger motifs, were shown to be critical residues whereas
Leu3, Isol16 and Leu10 were critical for nuclear export [93].
It has been shown by a yeast two hybrid system that TIS11
specifically associates with nucleoporin/Nup214 which is
part of the nuclear pore on the cytoplasmic face of the
pore complex [94] and this protein probably associates with
the linker region between the zinc finger motifs to mediate
nuclear localisation of TIS11. On the other hand nuclear
export seems to be regulated through CRM1 since inhibition
of CRM1 resulted in nuclear accumulation of TIS11 [93].
When cells are stimulated with a strong stress signal such
as heat shock, TIS11 co-localises with TIA-1 in stress granules
[95]. Localisation of TIS11 in stress granules also occurs
when cells are treated with FCCP (p-trifluoromethoxy car-
bonyl cyanide phenyl hydrazone, a mitochondrial inhibitor),
and oxidative stress but MK2 phosphorylation of TIS11
promotes its complex formation with 14-3-3 protein and
excludes it from stress granules [96, 97]. Both zinc fingers
of rat TIS11 are absolutely necessary for localisation in stress
granules, especially amino acids Tyr105, Tyr113, Phe119, Gly109,
and Gly114 [95]. On the contrary it was shown that arsenite
treatment excludes TIS11 from stress granules through
MK2 mediated or p38 and c-jun N-terminal kinase (JNK)
mediated phosphorylation [47, 96]. TIS11 and TIS11b also
localise to processing bodies (P-bodies), which are cytoplas-
mic foci of mRNAs and enzymes that have been proposed as
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sites of mRNA decay and translational silencing [42, 97, 98].
TIS11 and TIS11b appear to deliver ARE containing mRNAs
to processing bodies for translational silencing and mRNA
decay [98]. Overexpression of TIS11 and TIS11b resulted
in stable association between stress granules and processing
bodies suggesting that the TIS11 family plays an active role
in tethering stress granules to processing bodies [97]. Stress
granules are considered sites where mRNA is sorted for
storage, reinitiation of translation or degradation [97, 99].
Interestingly, formation of processing bodies is absolutely
necessary for RNA interference activity and translation
arrest or mRNA degradation through siRNA and miRNA
[100]. Thus, TIS11 family and miRNA posttranscriptional
functions take place in the same subcellular location as
well as possibly being interdependent and sharing mRNA
degradation machinery [48].
7. TIS11 Family in Cell Functions and Disease
Overexpression of TIS11 family members induces apoptosis
in a variety of cell lines including HeLa, U20S, SAOS2,
and 3T3 [101, 102] and B-cell lymphoma cells [77] cells.
Induction of apoptosis by all three TIS11 family members
was completely abrogated in the presence of Bcl-2 or CrmA
[101]. TIS11 synergistically induced apoptosis with TNF-
α in 3T3 cells and the zinc fingers and the N-terminal
domain of TIS11 are absolutely critical for this eﬀect [102].
Mutant TIS11 lacking the zinc finger motifs failed to induce
apoptosis and localised in the nucleus, whereas the wild type
TIS11 localised in the cytoplasm [102]. The TIS11 family
may regulate degradation of cell survival proteins such as,
Bcl-2, directly. Bcl-2 mRNA contains a Class II ARE motif in
the 3′UTR with at least one UUAUUUAUU nonamer which
is conserved between diﬀerent species and this sequence
controls the stability of Bcl-2 [103]. RNA electrophoretic
shift assays have confirmed an interaction between TIS11b
and the Bcl-2 ARE (Murphy et al., unpublished observa-
tions). Because TIS11 also destabilises several mRNAs whose
overexpression is related to malignant change, it has been
suggested that they may form a class of tumour suppressor
genes. In support of this hypothesis, it has been reported that
injection of mast cells transformed with v-H-Ras resulted in
tumour formation in mice as early as 6 weeks after injection
due to production of autocrine IL-3 [104]. Transfection
with v-H-Ras clones overexpressing TIS11 delayed tumour
formation by at least 4 weeks [104]. Another study correlated
response to cisplatin in head and neck squamous cell car-
cinoma cell lines with levels of TIS11b expression. Tumour
cells expressing TIS11b underwent apoptosis following drug
exposure, while tumour cells with low/absent levels of
TIS11b were resistant to apoptosis, but became sensitive
after transfection of cells with a TIS11b expressing plasmid
[36]. Interestingly, significant downregulation of inhibitor of
apoptosis protein 2 (cIAP2) but not Bcl-2 mRNA was seen
in these cells even though both these mRNAs contain class II
AREs [36].
TIS11 (but not TIS11b) specifically interacts with the
Tax protein from either bovine leukaemia virus or human
T lymphotropic virus 1 (HTLV-1) through the C-terminal
domain [46]. In the presence of TIS11, Tax was less
oncogenic probably due to inhibition of Tax transactivation
activity [46]. Interestingly TIS11 was able to abrogate TNF-
α induction by Tax in unstimulated RAW264.7 cells [46].
TIS11b expression is upregulated in humanHTLV-1-infected
cells by Tax transactivator protein which binds to two TIS11b
upstream control elements [105].
TIS11b was found to be one of the genes that are over
expressed in cell lines and primary cells expressing the
AML1-ETO fusion protein, that is, found in 40% of Acute
Myeloid Leukaemia subtype M2 [62]. When ectopically
expressed TIS11b promoted myeloid progenitor L-G cell
proliferation and inhibited diﬀerentiation [62]. Intriguingly,
siRNA mediated TIS11b knockdown in murine embryonic
stem cells promoted their diﬀerentiation to cardiomyocytes
[106]. Increased expression of TIS11b was reported in
primary breast tumours [107] and hepatocellular carcinomas
[108]. In addition, TIS11, TIS11b, and TIS11d have been
reported to be over-expressed in a variety of the NCI 60 panel
of human cancer cell lines [109].
The involvement of the TIS11 family in inflammatory
disease was one of the earliest reported disease associations
of this family. TIS11 knockout mice developed a generalised
autoimmune-like disease that was largely controlled by the
addition of neutralising anti-TNF antibodies [44]. TIS11,
in particular, has been reported to mediate degradation of
inflammatory cytokine mRNAs (see Table 1 and references
therein). Recently, targeting TIS11 has been shown to have
therapeutic potential in an animal model of inflammatory
bone loss [110].
8. Conclusion
The TIS11 family of proteins mediate posttranscriptional
gene regulation, which appears to be important in a range
of physiological and pathological processes. A number of
important gaps in our knowledge still exist and require
further study.We have limited knowledge ofmRNA targets of
TIS11 family members and whether individual TIS11 family
members target distinct, overlapping, or identical targets
to other family members. A few studies have suggested
inhibition of translation may also be mediated by the TIS11
family as well as mRNA degradation and this requires further
elucidation. A most interesting line of enquiry concerns the
relationship of TIS11 family mediated posttranscriptional
regulation to miRNA and siRNA mediated posttranscrip-
tional regulation. Finally, their role in cell functions and
disease have already provided evidence that they may be
useful therapeutic targets in inflammatory diseases and
cancer. Further studies are likely to identify other important
regulatory mechanisms for this family in health and disease.
Abbreviations
ARE: Adenine uridine rich elements
AU: Adenine uridine
CLL: Chronic lymphocytic leukemia
LPS: Lipopolysaccharide
MAPK: Mitogen activated protein kinase
8 Journal of Biomedicine and Biotechnology
miRNA: Micro RNA
MK2: p38-regulated MAPK activated protein kinase 2
PARN: PolyA specific ribonuclease
siRNA: Short interfering RNA
TPA: 12-O-tetradecanoylphorbol-13-acetate.
References
[1] P. J. Blackshear, R. S. Phillips, S. Ghosh, S. V. B. Ramos,
E. K. Richfield, and W. S. Lai, “Zfp36l3, a rodent X chro-
mosome gene encoding a placenta-specific member of the
tristetraprolin family of CCCH tandem zinc finger proteins,”
Biology of Reproduction, vol. 73, no. 2, pp. 297–307, 2005.
[2] Q. Ma, D. Wadleigh, T. Chi, and H. Herschman, “The
Drosophila TIS11 homologue encodes a developmentally
controlled gene,” Oncogene, vol. 9, no. 11, pp. 3329–3334,
1994.
[3] Q. Ma and H. R. Herschman, “The yeast homologue YTIS11,
of the mammalian TIS11 gene family is a non-essential,
glucose repressible gene,” Oncogene, vol. 10, no. 3, pp. 487–
494, 1995.
[4] M. J. Thompson, W. S. Lai, G. A. Taylor, and P. J. Blackshear,
“Cloning and characterization of two yeast genes encoding
members of the CCCH class of zinc finger proteins: zinc
finger-mediated impairment of cell growth,” Gene, vol. 174,
no. 2, pp. 225–233, 1996.
[5] P. J. Blackshear, “Tristetraprolin and other CCCH tandem
zinc-finger proteins in the regulation of mRNA turnover,”
Biochemical Society Transactions, vol. 30, no. 6, pp. 945–952,
2002.
[6] C. J. Wilusz, M. Wormington, and S. W. Peltz, “The cap-to-
tail guide to mRNA turnover,” Nature Reviews Molecular Cell
Biology, vol. 2, no. 4, pp. 237–246, 2001.
[7] T. Bakheet, B. R. G. Williams, and K. S. A. Khabar, “ARED
2.0: an update of AU-rich element mRNA database,” Nucleic
Acids Research, vol. 31, no. 1, pp. 421–423, 2003.
[8] E. Carballo, W. S. Lai, and P. J. Blackshear, “Feedback inhi-
bition of macrophage tumor necrosis factor-α production by
tristetraprolin,” Science, vol. 281, no. 5379, pp. 1001–1005,
1998.
[9] M. T. Worthington, J. W. Pelo, M. A. Sachedina, J. L.
Applegate, K. O. Arseneau, and T. T. Pizarro, “RNA binding
properties of the AU-rich element-binding recombinant
Nup475/TIS11/tristetraprolin protein,” The Journal of Biolog-
ical Chemistry, vol. 277, no. 50, pp. 48558–48564, 2002.
[10] P. J. Blackshear,W. S. Lai, E. A. Kennington, et al., “Character-
istics of the interaction of a synthetic human tristetraprolin
tandem zinc finger peptide with AU-rich element-containing
RNA substrates,” The Journal of Biological Chemistry, vol.
278, no. 22, pp. 19947–19955, 2003.
[11] B. Y. Brewer, J. Malicka, P. J. Blackshear, and G. M. Wilson,
“RNA sequence elements required for high aﬃnity binding
by the zinc finger domain of tristetraprolin: conformational
changes coupled to the bipartite nature of AU-rich mRNA-
destabilizing motifs,” The Journal of Biological Chemistry, vol.
279, no. 27, pp. 27870–27877, 2004.
[12] W. S. Lai, D. M. Carrick, and P. J. Blackshear, “Influence of
nonameric AU-rich tristetraprolin-binding sites on mRNA
deadenylation and turnover,” The Journal of Biological Chem-
istry, vol. 280, no. 40, pp. 34365–34377, 2005.
[13] S. A. Bustin, X.-F. Nie, R. C. Barnard, et al., “Cloning and
characterization of ERF-1, a human member of the Tis11
family of early-response genes,” DNA and Cell Biology, vol.
13, no. 5, pp. 449–459, 1994.
[14] S. A. Brooks, J. E. Connoly, and W. F. C. Rigby, “The
role of mRNA turnover in the regulation of tritetraprolin
expression: evidence for an extracellular signal-regulated
kinase-specific, AU-rich element-dependent, autoregulatory
pathway,” The Journal of Immunology, vol. 172, no. 12, pp.
7263–7271, 2004.
[15] E. Carballo, W. S. Lai, and P. J. Blackshear, “Evidence that
tristetraprolin is a physiological regulator of granulocyte-
macrophage colony-stimulating factor messenger RNA dead-
enylation and stability,” Blood, vol. 95, no. 6, pp. 1891–1899,
2000.
[16] G. Stoecklin, X.-F. Ming, R. Looser, and C. Moroni, “Somatic
mRNA turnover mutants implicate tristetraprolin in the
interleukin-3 mRNA degradation pathway,” Molecular and
Cellular Biology, vol. 20, no. 11, pp. 3753–3763, 2000.
[17] G. Stoecklin, P. Stoeckle, M. Lu, O. Muehlemann, and
C. Moroni, “Cellular mutants define a common mRNA
degradation pathway targeting cytokine AU-rich elements,”
RNA, vol. 7, no. 11, pp. 1578–1588, 2001.
[18] H. Sawaoka, D. A. Dixon, J. A. Oates, and O. Boutaud,
“Tristetraprolin binds to the 3′-untranslated region of
cyclooxygenase-2 mRNA: a polyadenylation variant in a
cancer cell line lacks the binding site,” The Journal of
Biological Chemistry, vol. 278, no. 16, pp. 13928–13935, 2003.
[19] H. Yu, S. Stasinopoulos, P. Leedman, and R. L. Medcalf,
“Inherent instability of plasminogen activator inhibitor type
2 mRNA is regulated by tristetraprolin,” The Journal of
Biological Chemistry, vol. 278, no. 16, pp. 13912–13918, 2003.
[20] P. Briata, C. Ilengo, G. Corte, et al., “The Wnt/β-catenin→
Pitx2 pathway controls the turnover of Pitx2 and other
unstable mRNAs,” Molecular Cell, vol. 12, no. 5, pp. 1201–
1211, 2003.
[21] R. L. Ogilvie, M. Abelson, H. H. Hau, I. Vlasova, P. J.
Blackshear, and P. R. Bohjanen, “Tristetraprolin down-
regulates IL-2 gene expression through AU-rich element-
mediatedmRNA decay,” The Journal of Immunology, vol. 174,
no. 2, pp. 953–961, 2005.
[22] S. I. Gringhuis, J. J. Garcı´a-Vallejo, B. van Het Hof, and W.
van Dijk, “Convergent actions of IκB kinase β and protein
kinase C δ modulate mRNA stability through phosphoryla-
tion of 14-3-3 β complexed with tristetraprolin,” Molecular
and Cellular Biology, vol. 25, no. 15, pp. 6454–6463, 2005.
[23] U. Jalonen, R. Nieminen, K. Vuolteenaho, H. Kankaan-
ranta, and E. Moilanen, “Down-regulation of tristetraprolin
expression results in enhanced IL-12 and MIP-2 production
and reduced MIP-3α synthesis in activated macrophages,”
Mediators of Inflammation, vol. 2006, Article ID 40691, 8
pages, 2006.
[24] I. Sauer, B. Schaljo, C. Vogl, et al., “Interferons limit
inflammatory responses by induction of tristetraprolin,”
Blood, vol. 107, no. 12, pp. 4790–4797, 2006.
[25] M. Marderosian, A. Sharma, A. P. Funk, et al., “Tristetrapro-
lin regulates cyclin D1 and c-MycmRNA stability in response
to rapamycin in an Akt-dependent manner via p38 MAPK
signaling,” Oncogene, vol. 25, no. 47, pp. 6277–6290, 2006.
[26] W. D. Patino, J.-G. Kang, S. Matoba, O. Y. Mian, B.
R. Gochuico, and P. M. Hwang, “Atherosclerotic plaque
macrophage transcriptional regulators are expressed in blood
and modulated by tristetraprolin,” Circulation Research, vol.
98, no. 10, pp. 1282–1289, 2006.
[27] W. S. Lai, J. S. Parker, S. F. Grissom, D. J. Stumpo, and P. J.
Blackshear, “Novel mRNA targets for tristetraprolin (TTP)
Journal of Biomedicine and Biotechnology 9
identified by global analysis of stabilized transcripts in TTP-
deficient fibroblasts,” Molecular and Cellular Biology, vol. 26,
no. 24, pp. 9196–9208, 2006.
[28] D. Frasca, A. M. Landin, J. P. Alvarez, P. J. Blackshear, R.
L. Riley, and B. B. Blomberg, “Tristetraprolin, a negative
regulator of mRNA stability, is increased in old B cells and
is involved in the degradation of E47 mRNA,” The Journal of
Immunology, vol. 179, no. 2, pp. 918–927, 2007.
[29] K. Essafi-Benkhadir, C. Onesto, E. Stebe, C. Moroni, and
G. Page`s, “Tristetraprolin inhibits ras-dependent tumor vas-
cularization by inducing vascular endothelial growth factor
mRNA degradation,” Molecular Biology of the Cell, vol. 18,
no. 11, pp. 4648–4658, 2007.
[30] G. Stoecklin, S. A. Tenenbaum, T. Mayo, et al., “Genome-
wide analysis identifies interleukin-10 mRNA as target of
tristetraprolin,” The Journal of Biological Chemistry, vol. 283,
no. 17, pp. 11689–11699, 2008.
[31] T. J. Horner, W. S. Lai, D. J. Stumpo, and P. J. Blackshear,
“Stimulation of polo-like kinase 3 mRNA decay by triste-
traprolin,” Molecular and Cellular Biology, vol. 29, no. 8, pp.
1999–2010, 2009.
[32] W. S. Lai, E. Carballo, J. M. Thorn, E. A. Kennington, and
P. J. Blackshear, “Interactions of CCCH zinc finger proteins
with mRNA. Binding of tristetraprolin-related zinc finger
proteins to AU-rich elements and destabilization of mRNA,”
The Journal of Biological Chemistry, vol. 275, no. 23, pp.
17827–17837, 2000.
[33] W. S. Lai and P. J. Blackshear, “Interactions of CCCH zinc
finger proteins with mRNA. Tristetraprolin-mediated AU-
rich element-dependent mRNA degradation can occur in the
absence of a poly(A) tail,” The Journal of Biological Chemistry,
vol. 276, no. 25, pp. 23144–23154, 2001.
[34] G. Stoecklin, M. Colombi, I. Raineri, et al., “Functional
cloning of BRF1, a regulator of ARE-dependent mRNA
turnover,” The EMBO Journal, vol. 21, no. 17, pp. 4709–4718,
2002.
[35] D. Ciais, N. Cherradi, S. Bailly, et al., “Destabilization of
vascular endothelial growth factor mRNA by the zinc-finger
protein TIS11b,” Oncogene, vol. 23, no. 53, pp. 8673–8680,
2004.
[36] S. K. Lee, S. B. Kim, J. S. Kim, et al., “Butyrate response factor
1 enhances cisplatin sensitivity in human head and neck
squamous cell carcinoma cell lines,” International Journal of
Cancer, vol. 117, no. 1, pp. 32–40, 2005.
[37] S. E. Bell, M. J. Sanchez, O. Spasic-Boskovic, et al., “The RNA
binding protein Zfp36l1 is required for normal vascularisa-
tion and post-transcriptionally regulates VEGF expression,”
Developmental Dynamics, vol. 235, no. 11, pp. 3144–3155,
2006.
[38] H. Duan, N. Cherradi, J.-J. Feige, and C. Jefcoate, “cAMP-
dependent posttranscriptional regulation of steroidogenic
acute regulatory (STAR) protein by the zinc finger protein
ZFP36L1/TIS11b,” Molecular Endocrinology, vol. 23, no. 4,
pp. 497–509, 2009.
[39] W. S. Lai, E. A. Kennington, and P. J. Blackshear, “Interactions
of CCCH zinc finger proteins with mRNA: non-binding
tristetraprolin mutants exert an inhibitory eﬀect on degra-
dation of AU-rich element-containing mRNAs,” The Journal
of Biological Chemistry, vol. 277, no. 11, pp. 9606–9613, 2002.
[40] W. S. Lai, E. A. Kennington, and P. J. Blackshear, “Tris-
tetraprolin and its family members can promote the cell-
free deadenylation of AU-rich element-containing mRNAs
by poly(A) ribonuclease,” Molecular and Cellular Biology, vol.
23, no. 11, pp. 3798–3812, 2003.
[41] J. Lykke-Andersen and E. Wagner, “Recruitment and activa-
tion of mRNA decay enzymes by two ARE-mediated decay
activation domains in the proteins TTP and BRF-1,” Genes
and Development, vol. 19, no. 3, pp. 351–361, 2005.
[42] M. Fenger-Grøn, C. Fillman, B. Norrild, and J. Lykke-
Andersen, “Multiple processing body factors and the ARE
binding protein TTP activate mRNA decapping,” Molecular
Cell, vol. 20, no. 6, pp. 905–915, 2005.
[43] C.-Y. Chen, R. Gherzi, S.-E. Ong, et al., “AU binding proteins
recruit the exosome to degrade ARE-containing mRNAs,”
Cell, vol. 107, no. 4, pp. 451–464, 2001.
[44] G. A. Taylor, E. Carballo, D. M. Lee, et al., “A pathogenetic
role for TNFα in the syndrome of cachexia, arthritis, and
autoimmunity resulting from tristetraprolin (TTP) defi-
ciency,” Immunity, vol. 4, no. 5, pp. 445–454, 1996.
[45] K. Suzuki, H. Nakajima, K. Ikeda, et al., “IL-4-Stat6 signaling
induces tristetraprolin expression and inhibits TNF-α pro-
duction in mast cells,” Journal of Experimental Medicine, vol.
198, no. 11, pp. 1717–1727, 2003.
[46] J.-C. Twizere, V. Kruys, L. Lefe`bvre, et al., “Interaction of
retroviral tax oncoproteins with tristetraprolin and regula-
tion of tumor necrosis factor-α expression,” Journal of the
National Cancer Institute, vol. 95, no. 24, pp. 1846–1859,
2003.
[47] W. F. C. Rigby, K. Roy, J. Collins, et al., “Structure/function
analysis of tristetraprolin (TTP): p38 stress-activated protein
kinase and lipopolysaccharide stimulation do not alter TTP
function,” The Journal of Immunology, vol. 174, no. 12, pp.
7883–7893, 2005.
[48] Q. Jing, S. Huang, S. Guth, et al., “Involvement of microRNA
in AU-Rich element-mediated mRNA instability,” Cell, vol.
120, no. 5, pp. 623–634, 2005.
[49] S. Dorner, L. Lum, M. Kim, R. Paro, P. A. Beachy, and
R. Green, “A genomewide screen for components of the
RNAi pathway inDrosophila cultured cells,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 103, no. 32, pp. 11880–11885, 2006.
[50] A. J. Asirvatham, C. J. Gregorie, Z. Hu, W. J. Magner,
and T. B. Tomasi, “MicroRNA targets in immune genes
and the Dicer/Argonaute and ARE machinery components,”
Molecular Immunology, vol. 45, no. 7, pp. 1995–2006, 2008.
[51] R. N. DuBois, M. W. McLane, K. Ryder, L. F. Lau, and D.
Nathans, “A growth factor-inducible nuclear protein with a
novel cysteine/histidine repetitive sequence,” The Journal of
Biological Chemistry, vol. 265, no. 31, pp. 19185–19191, 1990.
[52] G. A. Taylor, W. S. Lai, R. J. Oakey, et al., “The human
TTP protein: sequence, alignment with related proteins, and
chromosomal localization of the mouse and human genes,”
Nucleic Acids Research, vol. 19, no. 12, p. 3454, 1991.
[53] B. C. Varnum, R. W. Lim, V. P. Sukhatme, and H. R.
Herschman, “Nucleotide sequence of a cDNA encoding
TIS11, a message induced in Swiss 3T3 cells by the tumor
promoter tetradecanoyl phorbol acetate,” Oncogene, vol. 4,
no. 1, pp. 119–120, 1989.
[54] J. J. Murphy and J. D. Norton, “Cell-type-specific early
response gene expression during plasmacytoid diﬀerentia-
tion of human B lymphocytic leukemia cells,” Biochimica et
Biophysica Acta, vol. 1049, no. 3, pp. 261–271, 1990.
[55] Z.-Q. Ning, J. D. Norton, J. Li, and J. J. Murphy, “Distinct
mechanisms for rescue from apoptosis in Ramos human B
cells by signaling through CD40 and interleukin-4 receptor:
role for inhibition of an early response gene, Berg36,”
10 Journal of Biomedicine and Biotechnology
European Journal of Immunology, vol. 26, no. 10, pp. 2356–
2363, 1996.
[56] X.-F. Nie, K. N. Maclean, V. Kumar, I. A. McKay, and S. A.
Bustin, “ERF-2, the human homologue of themurine TIS11d
early response gene,”Gene, vol. 152, no. 2, pp. 285–286, 1995.
[57] P. J. Blackshear, R. S. Phillips, J. Vazquez-Matias, and
H. Mohrenweiser, “Polymorphisms in the genes encoding
members of the tristetraprolin family of human tandem
CCCH zinc finger proteins,” Progress in Nucleic Acid Research
and Molecular Biology, vol. 75, pp. 43–68, 2003.
[58] D.M. Carrick, P. Chulada, R. Donn, et al., “Genetic variations
in ZFP36 and their possible relationship to autoimmune
diseases,” Journal of Autoimmunity, vol. 26, no. 3, pp. 182–
196, 2006.
[59] D. J. Stumpo, N. A. Byrd, R. S. Phillips, et al., “Chorioal-
lantoic fusion defects and embryonic lethality resulting from
disruption of Zfp36L1, a gene encoding a CCCH tandem zinc
finger protein of the tristetraprolin family,” Molecular and
Cellular Biology, vol. 24, no. 14, pp. 6445–6455, 2004.
[60] S. B. V. Ramos, D. J. Stumpo, E. A. Kennington, et al.,
“The CCCH tandem zinc-finger protein Zfp36l2 is crucial
for female fertility and early embryonic development,”
Development, vol. 131, no. 19, pp. 4883–4893, 2004.
[61] H. Cao, J. S. Tuttle, and P. J. Blackshear, “Immunologi-
cal characterization of tristetraprolin as a low abundance,
inducible, stable cytosolic protein,” The Journal of Biological
Chemistry, vol. 279, no. 20, pp. 21489–21499, 2004.
[62] H. Shimada, H. Ichikawa, S. Nakamura, et al., “Analysis of
genes under the downstream control of the t(8;21) fusion
protein AML1-MTG8: overexpression of the TIS11b (ERF-
1, cMG1) gene induces myeloid cell proliferation in response
to G-CSF,” Blood, vol. 96, no. 2, pp. 655–663, 2000.
[63] T. Ino, H. Yasui, M. Hirano, and Y. Kurosawa, “Identification
of a member of the TIS11 early response gene family at
the insertion point of a DNA fragment containing a gene
for the T-cell receptor β chain in an acute T-cell leukemia,”
Oncogene, vol. 11, no. 12, pp. 2705–2710, 1995.
[64] B. T. Amann, M. T. Worthington, and J. M. Berg, “A Cys3His
zinc-binding domain from Nup475/tristetraprolin: a novel
fold with a disklike structure,” Biochemistry, vol. 42, no. 1,
pp. 217–221, 2003.
[65] B. P. Hudson, M. A. Martinez-Yamout, H. J. Dyson, and P.
E. Wright, “Recognition of the mRNA AU-rich element by
the zinc finger domain of TIS11d,” Nature Structural and
Molecular Biology, vol. 11, no. 3, pp. 257–264, 2004.
[66] W. S. Lai, D. J. Stumpo, and P. J. Blackshear, “Rapid insulin-
stimulated accumulation of an mRNA encoding a proline-
rich protein,” The Journal of Biological Chemistry, vol. 265,
no. 27, pp. 16556–16563, 1990.
[67] A. N. Corps and K. D. Brown, “Insulin and insulin-like
growth factor I stimulate expression of the primary response
gene cMG1/TIS11b by a wortmannin-sensitive pathway in
RIE-1 cells,” FEBS Letters, vol. 368, no. 1, pp. 160–164, 1995.
[68] K. R. Mahtani, M. Brook, J. L. E. Dean, G. Sully, J. Saklatvala,
and A. R. Clark, “Mitogen-activated protein kinase p38
controls the expression and posttranslational modification
of tristetraprolin, a regulator of tumor necrosis factor alpha
mRNA stability,” Molecular and Cellular Biology, vol. 21, no.
19, pp. 6461–6469, 2001.
[69] C. R. Tchen, M. Brook, J. Saklatvala, and A. R. Clark, “The
stability of tristetraprolin mRNA is regulated by mitogen-
activated protein kinase p38 and by tristetraprolin itself,” The
Journal of Biological Chemistry, vol. 279, no. 31, pp. 32393–
32400, 2004.
[70] A. M. Fairhurst, J. E. Connolly, K. A. Hintz, et al., “Regula-
tion and localization of endogenous human tristetraprolin,”
Arthritis Research & Therapy, vol. 5, no. 4, pp. R214–R225,
2003.
[71] B. C. Varnum, R. W. Lim, D. A. Kujubu, et al., “Granulocyte-
macrophage colony-stimulating factor and tetradecanoyl
phorbol acetate induce a distinct, restricted subset of
primary-response TIS genes in both proliferating and ter-
minally diﬀerentiated myeloid cells,” Molecular and Cellular
Biology, vol. 9, no. 8, pp. 3580–3583, 1989.
[72] K. Ogawa, F. Chen, Y.-J. Kim, and Y. Chen, “Transcriptional
regulation of tristetraprolin by transforming growth factor-
β in human T cells,” The Journal of Biological Chemistry, vol.
278, no. 32, pp. 30373–30381, 2003.
[73] A. Raghavan, R. L. Robison, J. McNabb, C. R. Miller, D.
A. Williams, and P. R. Bohjanen, “HuA and tristetraprolin
are induced following T cell activation and display distinct
but overlapping RNA binding specificities,” The Journal of
Biological Chemistry, vol. 276, no. 51, pp. 47958–47965, 2001.
[74] K. Smoak and J. A. Cidlowski, “Glucocorticoids regulate
tristetraprolin synthesis and posttranscriptionally regulate
tumor necrosis factor alpha inflammatory signaling,” Molec-
ular and Cellular Biology, vol. 26, no. 23, pp. 9126–9135,
2006.
[75] F. T. Ishmael, X. Fang, M. R. Galdiero, et al., “Role of
the RNA-binding protein tristetraprolin in glucocorticoid-
mediated gene regulation,” The Journal of Immunology, vol.
180, no. 12, pp. 8342–8353, 2008.
[76] Z.-Q. Ning, T. Hirose, R. Deed, J. Newton, J. J. Murphy, and
J. D. Norton, “Early response gene signalling in bryostatin-
stimulated primary B chronic lymphocytic leukaemia cells in
vitro,” Biochemical Journal, vol. 319, part 1, pp. 59–65, 1996.
[77] M. Baou, A. Jewell, A. Muthurania, et al., “Involvement of
TIS11b, an AU-rich binding protein, in induction of apopto-
sis by rituximab in B cell chronic lymphocytic leukemia cells,”
Leukemia, vol. 23, pp. 986–989, 2009.
[78] S. Mathas, A. Rickers, K. Bommert, B. Do¨rken, and M. Y.
Mapara, “Anti-CD20-and B-cell receptor-mediated apopto-
sis: evidence for shared intracellular signaling pathways,”
Cancer Research, vol. 60, no. 24, pp. 7170–7176, 2000.
[79] S. Reppe, O. K. Olstad, E. Rian, V. T. Gautvik, K. M. Gautvik,
and R. Jemtland, “Butyrate response factor 1 is regulated
by parathyroid hormone and bone morphogenetic protein-
2 in osteoblastic cells,” Biochemical and Biophysical Research
Communications, vol. 324, no. 1, pp. 218–223, 2004.
[80] A. M. Chinn, D. Ciais, S. Bailly, E. Chambaz, J. LaMarre,
and J.-J. Feige, “Identification of two novel ACTH-responsive
genes encoding manganese-dependent superoxide dismutase
(SOD2) and the zinc finger protein TIS11b [tetradecanoyl
phorbol acetate (TPA)-inducible sequence 11b],” Molecular
Endocrinology, vol. 16, no. 6, pp. 1417–1427, 2002.
[81] G. A. Taylor, M. J. Thompson, W. S. Lai, and P. J. Blackshear,
“Mitogens stimulate the rapid nuclear to cytosolic translo-
cation of tristetraprolin, a potential zinc-finger transcription
factor,” Molecular Endocrinology, vol. 10, no. 2, pp. 140–146,
1996.
[82] M. Brook, C. R. Tchen, T. Santalucia, et al., “Posttranslational
regulation of tristetraprolin subcellular localization and
protein stability by p38 mitogen-activated protein kinase and
extracellular signal-regulated kinase pathways,” Molecular
and Cellular Biology, vol. 26, no. 6, pp. 2408–2418, 2006.
[83] G. A. Taylor, M. J. Thompson, W. S. Lai, and P. J. Blackshear,
“Phosphorylation of tristetraprolin, a potential zinc finger
transcription factor, by mitogen stimulation in intact cells
Journal of Biomedicine and Biotechnology 11
and by mitogen-activated protein kinase in vitro,” The
Journal of Biological Chemistry, vol. 270, no. 22, pp. 13341–
13347, 1995.
[84] W. Zhu, M. A. Brauchle, F. Di Padova, et al., “Gene sup-
pression by tristetraprolin and release by the p38 pathway,”
American Journal of Physiology, vol. 281, no. 2, pp. L499–
L508, 2001.
[85] C. A. Chrestensen, M. J. Schroeder, J. Shabanowitz, et al.,
“MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo
sites including Ser178, a site required for 14-3-3 binding,”
The Journal of Biological Chemistry, vol. 279, no. 11, pp.
10176–10184, 2004.
[86] L. Sun, G. Stoecklin, S. Van Way, et al., “Tristetrapro-
lin (TTP)-14-3-3 complex formation protects TTP from
dephosphorylation by protein phosphatase 2a and stabilizes
tumor necrosis factor-α mRNA,” The Journal of Biological
Chemistry, vol. 282, no. 6, pp. 3766–3777, 2007.
[87] E. Hitti, T. Iakovleva, M. Brook, et al., “Mitogen-activated
protein kinase-activated protein kinase 2 regulates tumor
necrosis factor mRNA stability and translation mainly by
altering tristetraprolin expression, stability, and binding
to adenine/uridine-rich element,” Molecular and Cellular
Biology, vol. 26, no. 6, pp. 2399–2407, 2006.
[88] B. A. Johnson, J. R. Stehn, M. B. Yaﬀe, and T. K. Blackwell,
“Cytoplasmic localization of tristetraprolin involves 14-3-3-
dependent and -independent mechanisms,” The Journal of
Biological Chemistry, vol. 277, no. 20, pp. 18029–18036, 2002.
[89] H. Cao, L. J. Deterding, J. D. Venable, et al., “Identification of
the anti-inflammatory protein tristetraprolin as a hyperphos-
phorylated protein by mass spectrometry and site-directed
mutagenesis,” Biochemical Journal, vol. 394, no. 1, pp. 285–
297, 2006.
[90] S. Maitra, C.-F. Chou, C. A. Luber, K.-Y. Lee, M. Mann, and
C.-Y. Chen, “The AU-rich element mRNA decay-promoting
activity of BRF1 is regulated by mitogen-activated protein
kinase-activated protein kinase 2,” RNA, vol. 14, no. 5, pp.
950–959, 2008.
[91] M. Schmidlin, M. Lu, S. A. Leuenberger, et al., “The ARE-
dependent mRNA-destabilizing activity of BRF1 is regulated
by protein kinase B,” The EMBO Journal, vol. 23, no. 24, pp.
4760–4769, 2004.
[92] R. S. Phillips, S. B. V. Ramos, and P. J. Blackshear, “Members
of the tristetraprolin family of tandem CCCH zinc finger
proteins exhibit CRM1-dependent nucleocytoplasmic shut-
tling,” The Journal of Biological Chemistry, vol. 277, no. 13,
pp. 11606–11613, 2002.
[93] T. Murata, Y. Yoshino, N. Morita, and N. Kaneda, “Identifica-
tion of nuclear import and export signals within the structure
of the zinc finger protein TIS11,” Biochemical and Biophysical
Research Communications, vol. 293, no. 4, pp. 1242–1247,
2002.
[94] J. A. Carman and S. G. Nadler, “Direct association of triste-
traprolin with the nucleoporin CAN/Nup214,” Biochemical
and Biophysical Research Communications, vol. 315, no. 2, pp.
445–449, 2004.
[95] T. Murata, N. Morita, K. Hikita, K. Kiuchi, K. Kiuchi, and N.
Kaneda, “Recruitment of mRNA-destabilizing protein TIS11
to stress granules is mediated by its zinc finger domain,”
Experimental Cell Research, vol. 303, no. 2, pp. 287–299, 2005.
[96] G. Stoecklin, T. Stubbs, N. Kedersha, et al., “MK2-induced
tristetraprolin:14-3-3 complexes prevent stress granule asso-
ciation and ARE-mRNA decay,” The EMBO Journal, vol. 23,
no. 6, pp. 1313–1324, 2004.
[97] N. Kedersha, G. Stoecklin, M. Ayodele, et al., “Stress granules
and processing bodies are dynamically linked sites of mRNP
remodeling,” Journal of Cell Biology, vol. 169, no. 6, pp. 871–
884, 2005.
[98] T. M. Franks and J. Lykke-Andersen, “TTP and BRF proteins
nucleate processing body formation to silence mRNAs with
AU-rich elements,”Genes and Development, vol. 21, no. 6, pp.
719–735, 2007.
[99] N. Cougot, S. Babajko, and B. Se´raphin, “Cytoplasmic foci
are sites of mRNA decay in human cells,” Journal of Cell
Biology, vol. 165, no. 1, pp. 31–40, 2004.
[100] A. Jakymiw, S. Lian, T. Eystathioy, et al., “Disruption of GW
bodies impairs mammalian RNA interference,” Nature Cell
Biology, vol. 7, no. 12, pp. 1267–1274, 2005.
[101] B. A. Johnson, M. Geha, and K. T. Blackwell, “Similar but
distinct eﬀects of the tristetraprolin/TIS11 immediate-early
proteins on cell survival,”Oncogene, vol. 19, no. 13, pp. 1657–
1664, 2000.
[102] B. A. Johnson and T. K. Blackwell, “Multiple tristetrapro-
lin sequence domains required to induce apoptosis and
modulate responses to TNFα through distinct pathways,”
Oncogene, vol. 21, no. 27, pp. 4237–4246, 2002.
[103] N. Schiavone, P. Rosini, A. Quattrone, et al., “A conserved
AU-rich element in the 3′ untranslated region of bcl-2mRNA
is endowed with a destabilizing function that is involved
in bcl-2 down-regulation during apoptosis,” The FASEB
Journal, vol. 14, no. 1, pp. 174–184, 2000.
[104] G. Stoecklin, B. Gross, X.-F. Ming, and C. Moroni, “A novel
mechanism of tumor suppression by destabilizing AU-rich
growth factor mRNA,” Oncogene, vol. 22, no. 23, pp. 3554–
3561, 2003.
[105] B. Li, T. Fink, P. Ebbesen, X. D. Liu, and V. Zachar, “Expres-
sion of butyrate response factor 1 in HTLV-1-transformed
cells and its transactivation by tax protein,” Archives of
Virology, vol. 148, no. 9, pp. 1787–1804, 2003.
[106] D. Wegmu¨ller, I. Raineri, B. Gross, E. J. Oakeley, and C.
Moroni, “A cassette system to study embryonic stem cell
diﬀerentiation by inducible RNA interference,” Stem Cells,
vol. 25, no. 5, pp. 1178–1185, 2007.
[107] M. C. Abba, H. Sun, K. A. Hawkins, et al., “Breast cancer
molecular signatures as determined by SAGE: correlation
with lymph node status,” Molecular Cancer Research, vol. 5,
no. 9, pp. 881–890, 2007.
[108] P. J. Zindy, A. L’Helgoualc’h, D. Bonnier, et al., “Upregulation
of the tumor suppressor gene menin in hepatocellular
carcinomas and its significance in fibrogenesis,” Hepatology,
vol. 44, no. 5, pp. 1296–1307, 2006.
[109] D. M. Carrick and P. J. Blackshear, “Comparative expression
of tristetraprolin (TTP) familymember transcripts in normal
human tissues and cancer cell lines,” Archives of Biochemistry
and Biophysics, vol. 462, no. 2, pp. 278–285, 2007.
[110] C. S. Patil, M. Liu, W. Zhao, et al., “Targeting mRNA stability
arrests inflammatory bone loss,” Molecular Therapy, vol. 16,
no. 10, pp. 1657–1664, 2008.
